Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.
In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus ...
The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...
Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, with therapeutic and preventive approaches advancing in parallel.
A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.
At the cellular level, HIV-1 transmission involves a highly coordinated process whereby the virus binds to CD4 receptors and one of two coreceptors—CCR5 (R5) or CXCR4 (X4)—on host immune cells, ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results